Image Credentials: Image Title: Long Island Faces High Burden of Sickle Cell Disease, Study Finds Source: (chatgpt.com) Date: May 2026. Attribution: This image was created using AI-generated imagery (chatgpt.com) by Open Chronicle and does not depict a real-world scene.
By Open Chronicle with Agencies
A new study has highlighted significant regional disparities in the treatment and severity of Sickle Cell Disease across New York State, with Long Island emerging as an area with a particularly high burden of severe cases.
Researchers from NYU School of Global Public Health analyzed more than 42,000 hospitalizations between 2009 and 2022. While New York City recorded the highest number of cases overall, Long Island stood out for having the largest proportion of hospitalizations classified as carrying a major risk of death, accounting for about 10% of cases.
“This suggests a high sickle cell disease burden on Long Island,” said study author Emeka Iloegbu, pointing to both the severity of illness and the cost of care in the region.
Sickle cell disease is the most common inherited blood disorder in the United States, affecting around 100,000 people. It is caused by a genetic mutation that alters hemoglobin, the protein responsible for carrying oxygen in red blood cells. The condition leads to misshapen cells that can block blood flow, causing severe pain, organ damage, strokes, and an increased risk of infections.
The study found that hospital stays and outcomes varied widely across regions. Central New York and the Hudson Valley reported the longest average hospital stays, while New York City had shorter stays and fewer high-risk cases. However, Long Island recorded the highest overall hospital charges, suggesting that patients there may be receiving more complex or intensive care.
The findings also revealed troubling trends over time. The proportion of hospitalizations involving severe illness rose from 13% in 2009 to 27% in 2022, while cases with a major risk of mortality increased from 3% to 13%. Researchers attributed part of this rise to disruptions caused by the COVID-19 pandemic, which affected access to care and worsened health outcomes.
Demographic data showed that 83% of hospitalized patients were Black, reflecting the higher prevalence of the disease among people of African descent. Young adults aged 18 to 29 accounted for the largest share of hospitalizations, a pattern researchers say may point to gaps in transitioning patients from pediatric to adult care systems.
“Understanding regional differences in sickle cell disease can help us identify and address gaps in care,” said Emmanuel Peprah, another author of the study.
Experts suggest that improving access to specialized care, increasing awareness among healthcare providers, and expanding funding for treatment could help reduce the burden on emergency departments and improve long-term outcomes for patients.
New York has historically been at the forefront of early detection, launching the first newborn screening program for sickle cell disease in the United States in 1975. However, shifting migration patterns mean that many patients now entering the healthcare system were not screened at birth, often relying on emergency care as their first point of contact.
Despite the challenges, Long Island is also emerging as a center for innovation in treatment. In a notable case last year, a patient in the region received a groundbreaking gene therapy that effectively eliminated the disease, offering hope for future advances.
The study’s findings underscore the need for targeted public health strategies to address disparities and ensure more consistent, effective care for those living with sickle cell disease.